

ARCA Files NDA For Bucindolol; First Genetically Targeted CV Therapy?

The Pink Sheet

By Pamela Taulbee

September 23, 2008

FDA has accepted an NDA for Gencaro (bucindolol), which could be the first cardiovascular drug approved with an accompanying pharmacogenomic test, ARCA Biopharma said Sept. 23.

"While currently available beta blockers are a mainstay in medicine, it is difficult for physicians to predict which patients will respond to which therapy," Michael Bristow, ARCA chairman, said in a release.

"Bucindolol interacts with certain polymorphism of adrenergic receptors that help regulate cardiac function, allowing us to predict patient clinical response using a simple genetic test."

For complete article, click [here](#) [hotlink to www.thepinksheet.com]